发明名称 |
Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
摘要 |
A method for determining whether a cancer patient is susceptible to treatment with a protein tyrosine kinase 2 (PTK2) inhibitor, comprising detecting the expression of the E-cadherin protein in a cancer sample of said cancer patient, wherein an E-cadherin protein immunoreactivity score (IRS) of 0-2 indicates that the cancer patient is susceptible to treatment with a PTK2 inhibitor. The invention further encompasses treatment of a patient with a protein tyrosine kinase 2 (PTK2) inhibitor if it has been so determined that said patient is susceptible to such treatment. |
申请公布号 |
US2012244141(A1) |
申请公布日期 |
2012.09.27 |
申请号 |
US201113237833 |
申请日期 |
2011.09.20 |
申请人 |
ADOLF GUENTHER;GARIN-CHESA PILAR;HIRT ULRICH;BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
发明人 |
ADOLF GUENTHER;GARIN-CHESA PILAR;HIRT ULRICH |
分类号 |
A61K39/395;A61K31/7105;A61K31/713;A61P35/00;G01N21/76;G01N33/574 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|